Articles published by Forlong Biotechnology

Forlong Biotechnology Announced CMC Readiness to Initiate GMP Batch Production to Support Upcoming Pivotal Clinical Trial for FL115 (IL-15 Superagonist) in Nonmuscle Invasive Bladder Cancer (NMIBC)

April 15, 2026

From Forlong Biotechnology

Via Business Wire

Forlong Biotechology to Present Preclinical Data from FL115, a novel interleukin-15 (IL-15) superagonist, and FL116, a PD-1/interleukin-18 (IL-18) bispecific antibody, at the 2026 AACR Annual Meeting

March 17, 2026

From Forlong Biotechnology

Via Business Wire

Forlong Biotechology Announced Activation of Phase Ib/II Study of FL115 (IL-15 Superagonist) in combination with anti-PD-1 Antibody for Patients with Advanced Solid Tumor and Acceptance of IND for FL115 Subcutaneous Injection by NMPA

January 07, 2026

From Forlong Biotechnology

Via Business Wire

Forlong Dosed First Patient in Phase 2 Clinical Trial of FL115, a novel interleukin-15 (IL-15) superagonist, for nonmuscle invasive bladder cancer (NMIBC)

October 30, 2025

From Forlong Biotechnology

Via Business Wire

Forlong Biotechology to Present Clinical Data from FL115, a novel interleukin-15 (IL-15) superagonist, in Late-breaking Session at 40th SITC Annual Meeting

October 30, 2025

From Forlong Biotechnology

Via Business Wire

Forlong Biotechology Announces Collaboration Agreement with Henlius to Develop Innovative Cancer Immunotherapy with an Engineered Cytokine

October 22, 2025

From Forlong Biotechnology

Via Business Wire

Forlong Biotechnology Receives Milestone Payment as Partner Submits IND for A Protein Therapy using its Proprietary Fbody® Technology

October 14, 2025

From Forlong Biotechnology

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.